CHAPTER 1. Industry Overview of Inflammatory Bowel Disease Treatment Market
1.1. Definition and Scope
1.1.1. Definition of Inflammatory Bowel Disease
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Inflammatory Bowel Disease Treatment Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Inflammatory Bowel Disease Treatment Market By Disease
1.2.3. Inflammatory Bowel Disease Treatment Market By Drug Class
1.2.4. Inflammatory Bowel Disease Treatment Market By Route of Administration
1.2.5. Inflammatory Bowel Disease Treatment Market By Distribution Channel
1.2.6. Inflammatory Bowel Disease Treatment Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Inflammatory Bowel Disease Treatment Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Inflammatory Bowel Disease Treatment Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2022
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Inflammatory Bowel Disease Treatment Market By Disease
4.1. Introduction
4.2. Inflammatory Bowel Disease Revenue By Disease
4.2.1. Inflammatory Bowel Disease Revenue (USD Million) and Forecast, By Disease, 2020-2032
4.2.2. Ulcerative Colitis
4.2.2.1. Ulcerative Colitis Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.3. Crohns Disease
4.2.3.1. Crohns Disease Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.4. Indeterminate Colitis
4.2.4.1. Indeterminate Colitis Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 5. Inflammatory Bowel Disease Treatment Market By Drug Class
5.1. Introduction
5.2. Inflammatory Bowel Disease Revenue By Drug Class
5.2.1. Inflammatory Bowel Disease Revenue (USD Million) and Forecast, By Drug Class, 2020-2032
5.2.2. TNF inhibitors
5.2.2.1. TNF inhibitors Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.3. Corticosteroids
5.2.3.1. Corticosteroids Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.4. Aminosalicylates
5.2.4.1. Aminosalicylates Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.5. JAK inhibitors
5.2.5.1. JAK inhibitors Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.6. Anti-integrin
5.2.6.1. Anti-integrin Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.7. IL inhibitors
5.2.7.1. IL inhibitors Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.8. Others
5.2.8.1. Others Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 6. Inflammatory Bowel Disease Treatment Market By Route of Administration
6.1. Introduction
6.2. Inflammatory Bowel Disease Revenue By Route of Administration
6.2.1. Inflammatory Bowel Disease Revenue (USD Million) and Forecast, By Route of Administration, 2020-2032
6.2.2. Injectable
6.2.2.1. Injectable Market Revenue (USD Million) and Growth Rate (%), 2020-2032
6.2.3. Oral
6.2.3.1. Oral Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 7. Inflammatory Bowel Disease Treatment Market By Distribution Channel
7.1. Introduction
7.2. Inflammatory Bowel Disease Revenue By Distribution Channel
7.2.1. Inflammatory Bowel Disease Revenue (USD Million) and Forecast, By Distribution Channel, 2020-2032
7.2.2. Online Pharmacy
7.2.2.1. Online Pharmacy Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.3. Retail Pharmacy
7.2.3.1. Retail Pharmacy Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.4. Hospital Pharmacy
7.2.4.1. Hospital Pharmacy Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 8. North America Inflammatory Bowel Disease Treatment Market By Country
8.1. North America Inflammatory Bowel Disease Treatment Market Overview
8.2. U.S.
8.2.1. U.S. Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
8.2.2. U.S. Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
8.2.3. U.S. Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
8.2.4. U.S. Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
8.3. Canada
8.3.1. Canada Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
8.3.2. Canada Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
8.3.3. Canada Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
8.3.4. Canada Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
8.4. North America PEST Analysis
CHAPTER 9. Europe Inflammatory Bowel Disease Treatment Market By Country
9.1. Europe Inflammatory Bowel Disease Treatment Market Overview
9.2. U.K.
9.2.1. U.K. Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.2.2. U.K. Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
9.2.3. U.K. Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
9.2.4. U.K. Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
9.3. Germany
9.3.1. Germany Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.3.2. Germany Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
9.3.3. Germany Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
9.3.4. Germany Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
9.4. France
9.4.1. France Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.4.2. France Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
9.4.3. France Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
9.4.4. France Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
9.5. Spain
9.5.1. Spain Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.5.2. Spain Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
9.5.3. Spain Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
9.5.4. Spain Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
9.6. Rest of Europe
9.6.1. Rest of Europe Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.6.2. Rest of Europe Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
9.6.3. Rest of Europe Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
9.6.4. Rest of Europe Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Inflammatory Bowel Disease Treatment Market By Country
10.1. Asia Pacific Inflammatory Bowel Disease Treatment Market Overview
10.2. China
10.2.1. China Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.2.2. China Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
10.2.3. China Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
10.2.4. China Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
10.3. Japan
10.3.1. Japan Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.3.2. Japan Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
10.3.3. Japan Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
10.3.4. Japan Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
10.4. India
10.4.1. India Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.4.2. India Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
10.4.3. India Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
10.4.4. India Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
10.5. Australia
10.5.1. Australia Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.5.2. Australia Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
10.5.3. Australia Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
10.5.4. Australia Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
10.6. South Korea
10.6.1. South Korea Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.6.2. South Korea Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
10.6.3. South Korea Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
10.6.4. South Korea Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.7.2. Rest of Asia-Pacific Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
10.7.3. Rest of Asia-Pacific Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
10.7.4. Rest of Asia-Pacific Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Inflammatory Bowel Disease Treatment Market By Country
11.1. Latin America Inflammatory Bowel Disease Treatment Market Overview
11.2. Brazil
11.2.1. Brazil Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
11.2.2. Brazil Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
11.2.3. Brazil Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
11.2.4. Brazil Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
11.3. Mexico
11.3.1. Mexico Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
11.3.2. Mexico Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
11.3.3. Mexico Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
11.3.4. Mexico Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
11.4. Rest of Latin America
11.4.1. Rest of Latin America Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
11.4.2. Rest of Latin America Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
11.4.3. Rest of Latin America Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
11.4.4. Rest of Latin America Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
11.5. Latin America PEST Analysis
CHAPTER 12. Middle East & Africa Inflammatory Bowel Disease Treatment Market By Country
12.1. Middle East & Africa Inflammatory Bowel Disease Treatment Market Overview
12.2. GCC
12.2.1. GCC Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
12.2.2. GCC Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
12.2.3. GCC Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
12.2.4. GCC Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
12.3. South Africa
12.3.1. South Africa Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
12.3.2. South Africa Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
12.3.3. South Africa Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
12.3.4. South Africa Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Drug Class, 2020-2032
12.4.2. Rest of Middle East & Africa Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Disease, 2020-2032
12.4.3. Rest of Middle East & Africa Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
12.4.4. Rest of Middle East & Africa Inflammatory Bowel Disease Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
12.5. Middle East & Africa PEST Analysis
CHAPTER 13. Player Analysis Of Inflammatory Bowel Disease Treatment Market
13.1. Inflammatory Bowel Disease Treatment Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Inflammatory Bowel Disease Treatment Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. Company Profile
14.1. Takeda Pharmaceutical Company Limited
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (USD Million), 2022
14.1.3.2. Takeda Pharmaceutical Company Limited 2022 Inflammatory Bowel Disease Business Regional Distribution
14.1.4. Product /Service and Specification
14.1.5. Recent Developments & Business Strategy
14.2. Pfizer Inc
14.3. Biogen
14.4. Novartis AG
14.5. Lilly
14.6. UCB S.A.
14.7. CELLTRION INC.
14.8. Merck & Co., Inc.,
14.9. Johnson & Johnson Services, Inc.
14.10. AbbVie Inc.
The inflammatory bowel disease treatment market size was valued at USD 13.39 billion in 2022.
The CAGR of inflammatory bowel disease is 5.3% during the analysis period of 2023 to 2032.
The key players operating in the global market are including Takeda Pharmaceutical Company Limited, Pfizer Inc, Biogen, Novartis AG, Lilly, UCB S.A., CELLTRION INC., Merck & Co., Inc., Johnson & Johnson Services, Inc., and AbbVie Inc.
North America held the dominating position in inflammatory bowel disease industry during the analysis period of 2023 to 2032.
Asia-Pacific region exhibited fastest growing CAGR for market of inflammatory bowel disease during the analysis period of 2023 to 2032.
The current trends and dynamics in the inflammatory bowel disease industry include increasing prevalence and diagnosis rates of inflammatory bowel disease, growing awareness about the importance of early detection and treatment, advancements in medical research leading to innovative therapies, and rising healthcare expenditure and government initiatives to improve patient care.
The hospital pharmacy distribution channels the maximum share of the inflammatory bowel disease industry.
Customer Satisfaction
Availability - we are always there when you need us
Fortune 50 Companies trust Acumen Research and Consulting
of our reports are exclusive and first in the industry
more data and analysis
reports published till date